RT Journal Article
SR Electronic
T1 Increased Mortality in Patients with Standard EEG Findings of “Diffuse Slowing”
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 19009621
DO 10.1101/19009621
A1 Wanzek, Rob
A1 Bormann, Nicholas
A1 Shabbir, Yaseen
A1 Saito, Taku
A1 Yamada, Thoru
A1 Shinozaki, Gen
YR 2019
UL http://medrxiv.org/content/early/2019/10/22/19009621.abstract
AB Background/Objectives We aim to confirm the association between the high risk score on bispectral electroencephalogram (BSEEG) and mortality by comparing outcomes for those with “diffuse slowing” and normal findings on standard EEG.Design This is a retrospective study conducted with patient chart data from March 2015 to March 2017.Setting Single center study at a tertiary care academic hospital in the Midwest region of the USA.Participants 1069 subjects aged 55 years and older who were on an inpatient floor or intensive care unit and received a standard 24-hour EEG.Measurements Primary outcome was all-cause mortality at 30-, 90-, 180-, and 365-days. Secondary outcomes were time-to-discharge, and discharge to home.Results Patients with “diffuse slowing” on standard EEG was significantly associated with 30-, 90-, 180-, and 365-day mortality (P < .001) compared to those with normal EEG findings when controlling for age, sex, and Carlson Comorbidity Index. Those with diffuse slowing also had a longer time to discharge (P < 0.001) and were less likely to discharge to home (P < 0.001) when controlling for the same factors. Findings were similar when limiting the study to only patients whose clinical status indicated “awake” at time of EEG, except for 30-day mortality.Conclusion Our findings show that a standard EEG finding of “diffuse slowing” for inpatients 55 year or older is associated with greater mortality. This study strengthens the importance of the association found between high BSEEG score and mortality.Competing Interest StatementGen Shinozaki is a co-founder of Predelix Medical LLC. Other authors have no disclosures.Funding StatementNo funding source was used relevant to this study.Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.YesData is available from author upon request.